Gastroenteropancreatic neuroendocrine tumours (GEP-NET) – Imaging and staging

Baumann, Tobias; Rottenburger, Christof; Nicolas, Guillaume; Wild, Damian

doi:10.1016/j.beem.2016.01.003

Cited by 96 publications

(104 citation statements)

References 79 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…2% and # 20%, mitotic count of [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]; and G3 tumors are poorly differentiated carcinomas characterized by aggressive behavior and poor survival (Ki-67 . 20% or mitotic count .…”

Section: Tumor Grading and Disease Stagingmentioning

confidence: 99%

Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions

et al. 2016

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to (1) summarize the main clinical features of gastroenteropancreatic neuroendocrine tumors; (2) describe the specific mechanisms of uptake of radiotracers and identify the relation of imaging phenotype with site of origin and tumor grade; and (3) recommend the best imaging modalities across the different tumor subtypes for imaging and for selecting candidates for peptide receptor radionuclide therapy.

show abstract

Section: Tumor Grading and Disease Stagingmentioning

confidence: 99%

Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In the presented case 68Ga-DOTATATE PET/ CT accurately showed the extent of the disease and confidently revealed the location of the primary tumor, demonstrating the utility of PET/CT using 68 Ga-DOTA-conjugated peptides in the accurate management of patients with gastro-enteropancreatic NETs [3]. …”

mentioning

confidence: 62%

Application of 68Ga-DOTA-TATE PET/CT in metastatic neuroendocrine tumor of gastrointestinal origin

Papadakis¹

2016

aog

View full text Add to dashboard Cite

A 65-year-old man underwent an abdominal ultrasound of acute abdominal pain, showing an incidental. Subsequently, a magnetic resonance imaging (MRI) scan of the abdomen revealed additional liver lesions, hyper-intense on T2-weighted images. Needle biopsy of the largest lesion showed a welldifferentiated neuroendocrine tumor (NET) of gastrointestinal origin. The patient underwent a whole-body positron emission tomography-computed tomography (PET/CT) scan using Ga-DOTATATE injection) excision of the tumors from the small bowel, the mesenteric lymph nodes and the liver lesions. Subsequently pathological evaluation of all excised specimens revealed primary grade-I NET in the terminal ileum with metastases to the liver and mesenteric lymph nodes.Since the majority of NETs overexpress SST receptors, they can be effectively targeted and localized using radiolabeled SST analogs [1,2]. In the presented case 68Ga-DOTATATE PET/ CT accurately showed the extent of the disease and confidently revealed the location of the primary tumor, demonstrating the utility of PET/CT using 68 Ga-DOTA-conjugated peptides in the accurate management of patients with gastro-enteropancreatic NETs [3].

show abstract

“…A more comprehensive study involving the evaluation of 3 different sstr2 antagonists-LM3, JR10 (p-NO 2 Interestingly, however, substitution of DOTA by the NODAGA chelator was able to substantially increase the binding affinity of the Ga(III)-NODAGA analogs, compared with the Ga(III)-DOTA analogs. That study illustrated the great potential of the antagonists, because even a low-affinity antagonist was shown to be slightly superior to a high-affinity agonist, outweighing the affinity differences.…”

Section: Second Generation Of Radiolabeled Sstr Antagonistsmentioning

confidence: 99%

“…Important improvements in recent years were the introduction of peptide receptor radionuclide therapy (PRRT) with radiolabeled sstr agonists, such as 90 Y-or 177 Lu-DOTATOC and 177 Lu-DOTATATE, and the introduction of sstr PET/CT with (mainly) 68 Ga-labeled sstr agonists, such as DOTATOC, DOTATATE, and DOTANOC (1). sstr PET/CT currently plays an important role in detection of the primary tumor, detection of an unknown primary tumor, staging, restaging, and assessment of the treatment response in patients with NETs (2). Furthermore-and most importantly-sstr scintigraphy and sstr PET/CT can distinguish patients who will qualify for and benefit from PRRT and treatment with SSA.…”

mentioning

confidence: 99%